{"title":"Expensive Drugs for Rare Diseases: \"Canada, We Have a Problem Here\".","authors":"Joel Lexchin","doi":"10.12927/hcpap.2023.27001","DOIUrl":null,"url":null,"abstract":"<p><p>This issue of <i>Healthcare Papers</i> on expensive drugs for rare diseases (EDRDs) is very timely. According to the recently released Patented Medicine Prices Review Board's 2021 annual report, EDRDs have gone from 1.7% of pharmaceutical expenditures in 2012 to 12.2% in 2021, with a compound annual growth rate between 2012 and 2021 of 31.7% compared to 6.0% for all prescription medicines (PMPRB 2022).</p>","PeriodicalId":35522,"journal":{"name":"Healthcare Papers","volume":"21 1","pages":"4-8"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Healthcare Papers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12927/hcpap.2023.27001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
This issue of Healthcare Papers on expensive drugs for rare diseases (EDRDs) is very timely. According to the recently released Patented Medicine Prices Review Board's 2021 annual report, EDRDs have gone from 1.7% of pharmaceutical expenditures in 2012 to 12.2% in 2021, with a compound annual growth rate between 2012 and 2021 of 31.7% compared to 6.0% for all prescription medicines (PMPRB 2022).
期刊介绍：
Integrating community-based health and social care has grabbed international attention as a way of addressing the needs of aging populations while contributing to health systems" sustainability. However, integrating initiatives in different jurisdictions work (or do not work) within very various.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
